PHVS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PH

Mkt Cap

$1.95B

Volume

1.11M

Next Earnings

November 11th

Loading chart

PH

PHVSPharvaris N.V. Ordinary Shares

PHVS

Pay with—

Available Balance0.00

PH

Mkt Cap

$2.08B

Volume

1.11M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The LancetPharvaris announced that Phase 3 RAPIDe-3 trial results for deucrictibant IR, an oral bradykinin B2 receptor antagonist for on-demand treatment of hereditary angioedema (HAE) attacks, were published in The Lancet. The drug achieved symptom relief in 1.28 hours and complete resolution in 11.95 hours, met its primary endpoint and all 11 secondary endpoints, and showed a well-tolerated safety profile. An NDA with the FDA (PDUFA target date April 23, 2027) and MAA with the EMA are currently under regulatory review.GlobeNewswire Inc. · Oct 8, 2026

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in TherapyPharvaris-funded analysis of real-world HAE management reveals significant gaps between guideline-recommended care and clinical practice. Study of 225 physicians and 279 patients identified key barriers to treatment adherence, including treatment burden, route of administration, and patient perception of attack severity. Findings highlight unmet needs and suggest oral daily treatment is preferred over injectable options, supporting Pharvaris' development of oral bradykinin B2 receptor antagonists.GlobeNewswire Inc. · Oct 5, 2026

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in ImmunologyPharvaris announced publication of a qualitative study assessing disease burden in AAE-C1INH patients and validating patient-reported outcome measures. The study findings informed the design of the ongoing Phase 3 CREAATE trial investigating deucrictibant for prophylaxis and on-demand treatment of AAE-C1INH attacks. Results demonstrated significant multifaceted disease burden with frequent painful attacks disrupting daily life, and validated the use of established PRO instruments for measuring treatment benefits.GlobeNewswire Inc. · Aug 6, 2026

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?Pharvaris director Johannes Schikan sold 37,600 shares worth $1.3 million in late June 2026, representing 10.66% of his direct holdings. The sale occurred under a Rule 10b5-1 trading plan following a 96.5% one-year stock price appreciation. Shortly after, the FDA accepted the company's New Drug Application for its lead drug deucrictibant for hereditary angioedema treatment, though the stock has remained relatively flat since the announcement.The Motley Fool · Jul 24, 2026

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary SharesPharvaris N.V., a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for hereditary angioedema and acquired angioedema, announced the pricing of an underwritten public offering of approximately 3.87 million ordinary shares at $29.68 per share, generating approximately $115 million in gross proceeds. The offering is expected to close on or about May 11, 2026. The company is preparing marketing authorization applications for deucrictibant immediate-release capsule and has an ongoing Phase 3 study (CHAPTER-3) with topline data anticipated in Q3 2026.GlobeNewswire Inc. · May 8, 2026

For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming NextDirector Johannes Gerardus Christiaan Petrus Schikan sold 7,100 shares of Pharvaris (1.80% of his direct holdings) for approximately $213,000 under a pre-scheduled trading plan. The modest sale is not indicative of any change in outlook. Investors should focus instead on upcoming clinical catalysts: Phase 3 CHAPTER-3 topline data expected in Q3 2026 and a planned U.S. NDA submission for deucrictibant IR in H1 2026, which will have far greater impact on the stock than insider trading activity.The Motley Fool · Apr 30, 2026

Why Bain Capital Is Selling Shares of This Biotech Stock NowBain Capital Life Sciences Investors sold 122,106 shares of Pharvaris N.V. during Q3 2025, reducing its position value by $21.23 million while maintaining a significant stake. The sale appears to be profit-taking rather than a negative sentiment shift.The Motley Fool · Nov 18, 2025

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsPharvaris, a biopharmaceutical company, has priced a public offering of 8,250,000 ordinary shares at $20.00 per share and pre-funded warrants to purchase 500,000 shares, expecting to raise approximately $175 million.GlobeNewswire Inc. · Jul 23, 2025

Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI CongressPharvaris presented data at the EAACI Congress 2025 supporting the potential of its oral bradykinin B2 receptor antagonist, deucrictibant, for the prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks.GlobeNewswire Inc. · Jun 16, 2025

Pharvaris Announces Annual Meeting of ShareholdersZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the annual general meeting of shareholders will take place on Friday, June 28, 2024, at 15:00 CEST (9:00 a.m. EDT).GlobeNewswire Inc. · Jun 11, 2024

to start trading

PH

PHVSPharvaris N.V. Ordinary Shares

PHVS

Pay with—

Available Balance0.00

Your PositionYou don't own any PHVS yet.

Related Tickers

Earnings